https://dxm-atlas.org/en/interactions/cbd-dominant-products/
CompareKey points for this combination
Direct measurements of how the body processes substances come from a specific study. That study did not find marked inhibition of the CYP2D6 enzyme [10].
General concepts in this text
Enzyme
A protein that helps chemical transformations in cells.
A transformation can build or break down a substance.
Sources: Enzyme
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
How well is this understood?
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
Can the amount reaching the body change?
ⓘ
CYP
A family of enzymes involved in chemically transforming drugs.
Metabolism can reduce or increase a substance’s activity.
Sources: CYP
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
- In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6. Finding below: Finding [10] · 1
- THC AUC increase versus THC-only product → The CBD-rich product also contained THC and increased THC AUC by 161% relative to the THC-only product, consistent with inhibition of oral THC clearance. Finding below: Finding [10] · 2
How can the effects add up?
ⓘ
Cannabinoid-related effects / functional impairment and secondary physical hazards
What remains unknown?
A CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
Sources
Check the review’s wording
*Direct PK evidence limited to a specific study; marked CYP2D6 inhibition not found [10]
- [10] Evaluation of Cytochrome P450 Mediated Cannabinoid Drug Interactions in Healthy Adult Participants · Open publication
Evidence and sources
Research publication
[10] · Evaluation of Cytochrome P450 Mediated Cannabinoid Drug Interactions in Healthy Adult Participants · 2023
Finding [10] · 1
- What was found?
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6.
Finding [10] · 2
- What was found?
The CBD-rich product also contained THC and increased THC AUC by 161% relative to the THC-only product, consistent with inhibition of oral THC clearance.
THC AUC increase versus THC-only product
What do AUC, Cmax and DXO mean?
161%
- What limits this finding?
A CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].